Osteonecrosis of the femoral head (ONFH) is one of the more common complications following the therapy of leukemia.
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Osteonecrosis is also a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the incidence reported in the literature is between 3 and 44%. 2, 3 The severity of osteonecrosis can range from asymptomatic to enervating presentations that cause serious pain, reduction in joint mobility and, finally, degenerative changes and progressive joint damage. 1, 4 There is no consensus on how ONFH needs to be managed in leukemic patients. Conservative treatments such as non-steroidal anti-inflammatory drugs (NSAIDs), physical therapy and protected weight bearing therapy 1, 5 are generally unsuccessful. Several studies have described recommended surgical interventions for early-stage ONFH, such as core decompression. 1, 6, 7 However, the results of these procedures varied markedly, with lower satisfactory outcomes. In addition, these patients usually required long-term immunosuppression and glucocorticoid (GC) therapy, and appeared physically frail with depressed immune competence. Consequently, these patients are generally at high risk of postoperative infections. 8 Thus, we feel a pressing need for an effective and non-invasive alternative approach in the therapy of leukemia-related ONFH. Extracorporeal shockwave therapy (ESWT) enables quicker and more effective responses than surgical procedures like core decompression and non-vascularized bone grafting for early-stage ONFH. 9 Recently, a basic study indicated that shock wave therapy produced microfractures, and activated cells to express osteogenic genes that in turn caused new bone formation.
19 Therefore, we retrospectively evaluated the effectiveness of focused highenergy shock wave therapy in a series of patients with early stage ONFH after allo-HSCT by assessing clinical and magnetic resonance imaging (MRI) results.
Between January 2012 and September 2014, we recruited 43 patients (that is, 86 hips) with early ONFH in adult survivors presenting with leukemia who received allo-HSCT (Table 1) . We included patients with Stage I, II, and III ONFH according to the Association Research Circulation Osseous classification, 9, 10 which was mentioned in the literature. We excluded patients with acute infection, other malignancies, coagulation disorders and cardiac arrhythmia that required a pacemaker, pregnancy, skeletal immaturity and poor compliance. 9 The cumulative dose of methylprednisolone (MP) from the initial diagnosis of leukemia to the confirmed diagnosis of ONFH after allo-HSCT was calculated, which included GC chemotherapy, GC therapy due to GvHD and GC therapy during blood transfusion. If dexamethasone or prednisone was used in the treatment of leukemia, all GC doses were converted to MP dose equivalents by a dose-conversion relationship. All patients had received intravenous steroids during anti-leukemia therapy. The underlying diagnosis was confirmed by X-ray and MRI analysis. All cases of ONFH at MRI study were bilateral. All ESWT procedures (Dornier Compact DELTA II, Munich, Germany) were performed without general or regional anesthesia by experienced physicians with the patient placed in the supine position on the operating table. Four to six points were located on the hardened layer around the necrotic lesion by C-arm imaging. 9 ESWT orthopedic settings were prepared and used according to previously described methods [9] [10] [11] as follows: number of levels, 3-4; each spot received a dose of 500-1000 pulses at an energy flux density of 40.44 mJ/mm 2 (level 3) and then a dose of 3000-4000 impulses at a frequency of 2 − 3 Hz. Each patient underwent two consecutive therapy sessions that were spaced one week apart. After ESWT treatment, patients were instructed to walk on crutches with partial weight bearing on the affected leg for 4 − 6 weeks. Alendronate sodium tablets (at a dose of 70 mg p.o. qw for 12 months) were administered to each patient. An assessment of pain intensity (that is, by visual analog scale (VAS)) and hip function (that is, the Harris hip score (HHS)) was carried out before and after therapy. Radiographic assessment was performed using plain radiographs and MRI analysis. We used MRI findings to evaluate the changes in lesion size, the congruency of the articular surface and bone marrow edema. Radiographs and MRI of the affected hip were performed preoperatively at 6 months, 12 months and once a year thereafter. The primary end points of the study was the need for total hip arthroplasty (THA) during the course of treatment. Secondary end points included improvement in pain and function of the affected hip, and changes on analysis of X-ray and MRI images, which included the size of the lesion and evidence of bone marrow edema. All results were expressed as mean ± s.d. for the continuous variables and % for discrete variables. All data analyses were performed using SPSS version 16.0.0 software (SPSS; Chicago, IL, USA). We compared pain and HHSs before and after shock wave treatment using paired Student's t-tests. The overall clinical outcomes and changes in lesion size were compared statistically by Chi-square test analysis for statistical significance using a 95% confidence interval (P o 0.05).
In the current study, the treatment was well tolerated and none of the patients experienced severe side-effects. 89.5% (77/86) of the hips showed pain reduction and continued to improve over the follow-up period. The mean VAS score for both groups decreased from 6.9 ± 2.8 to 0.9 ± 1.7 (Po 0.001). The mean HHS for both groups increased from 70.1 ± 13.1 to 91.7 ± 13.8 (P o 0.01). At the last follow-up (that is, a minimum of 12-months), only two hips failed following femoral head collapse and required hip arthroplasty. ESWT might have the potential to curtail disease progression and to delay the need for THA. The MRI findings demonstrated progressive regression of ONFH. A significant reduction in bone marrow edema by MRI of ONFH was observed after shock wave treatment (47/86 hips (54.7%) vs 16/86 hips (18.6%), P o 0.01). The reduction in bone marrow edema correlated with clinical improvement in pain and hip function. There was a trend of decreased lesion size after ESWT (Figure 1) . However, the differences were not statistically significant (31.9 ± 12.1% vs 23.2 ± 10.0%, P = 0.071). The imaging studies showed stable images of the hip, including the obvious osteogenic signs of the femoral head, absence of progression in osteonecrotic staging and significantly improved concomitant bone marrow edema. We did not observe any evidence of systemic or neurovascular complications. Mild local edema and erythema at the treatment site in the greater trochanter area were noted in 37 of 86 hips (43.0%) in all patients. Observations noted that there was resolution of the edema within a few days.
Tauchmanovà et al. 12 suggested that osteonecrosis may be accelerated by a severe deficit in the reproductive capacity of bone marrow stromal stem cells after HSCT. In addition, older age, male gender and GC therapy given for acute and chronic GvHD were shown to independently increase the risk of osteonecrosis after allo-HSCT. 1, 12 In the presented case series almost all patients (n = 41, 95.3%) suffered from GvHD requiring long lasting steroid therapy, indicating the dominant role of GVHD in osteonecrosis after allo-HSCT. The shockwave treatment altered the natural course of hips affected by ONFH, and it was effective in the retardation or prevention of collapse of the femoral head in early ONFH.
11 EWST appeared to be more effective than core decompression and non-vascularized fibular grafting in patients with an early stage ONFH of 79% clinical improvement and 39% regression of the lesion on MRI. 9 It appears that the application of shockwave resulted in regenerative effects in hips with ONFH, which is consistent with our study results. Koo et al. 13 reported a correlation with hip pain and bone marrow edema in hips affected by ONFH. Our findings confirmed this and showed significant improvement in pain and function of affected hips and reduction in bone marrow edema on MRIs after shockwave treatment. However, the exact mechanism by which shock wave treatment results in clinical improvement remains unknown. Recent studies showed that ESWT induces neovascularization, upregulates angiogenesis-and osteogenesis-related growth factors, and promotes cell proliferation and differentiation leading to tissue regeneration. 11, 14, 15 Shock wave therapy promotes early release of angiogenic factors and subsequently induces cell proliferation and ingrowth of neovessels, which in turn may stimulate stromal cell growth, differentiation and promotion of bone healing. 15 Furthermore, ESWT significantly enhanced the angiogenic and osteogenic effects of bone marrow stromal cells mediated through the nitric oxide pathway in hips with osteonecrosis. 14 ESWT provided beneficial effects for hips that were affected by early ONFH with leukemia after allo-HSCT in the short term. It can rapidly and highly effectively resolve the suffering of bone marrow edema that is secondary to leukemia-related ONFH. However, the mechanisms and indications of ESWT remain unclear. Because the use of shock wave therapy is currently based on previous clinical observations and is limited, literate randomized trials comparing the approach with other currently used interventions are urgently required. 
